Pharming Group NV - Asset Resilience Ratio

Latest as of September 2025: 7.13%

Pharming Group NV (PHARM) has an Asset Resilience Ratio of 7.13% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Pharming Group NV to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€33.80 Million

≈ $39.51 Million USD Cash + Short-term Investments

Total Assets

€473.79 Million

≈ $553.90 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2005–2024)

This chart shows how Pharming Group NV's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Pharming Group NV to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Pharming Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Pharming Group NV worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€33.80 Million	7.13%
Total Liquid Assets	€33.80 Million	7.13%

Asset Resilience Insights

Limited Liquidity: Pharming Group NV maintains only 7.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pharming Group NV Industry Peers by Asset Resilience Ratio

Compare Pharming Group NV's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Pharming Group NV (2005–2024)

The table below shows the annual Asset Resilience Ratio data for Pharming Group NV.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	28.18%	€109.03 Million ≈ $127.47 Million	€386.88 Million ≈ $452.30 Million	-4.03pp
2023-12-31	32.21%	€137.31 Million ≈ $160.53 Million	€426.34 Million ≈ $498.44 Million	--
2022-12-31	0.00%	€0.00 ≈ $0.00	€425.80 Million ≈ $497.80 Million	--
2019-12-31	-0.26%	€-661.91K ≈ $-773.84K	€255.63 Million ≈ $298.86 Million	-5.84pp
2008-12-31	5.59%	€5.22 Million ≈ $6.10 Million	€93.40 Million ≈ $109.20 Million	-11.30pp
2005-12-31	16.88%	€6.92 Million ≈ $8.09 Million	€40.96 Million ≈ $47.89 Million	--

pp = percentage points

About Pharming Group NV

AS:PHARM Netherlands Biotechnology

Market Cap

$917.94 Million

€785.17 Million EUR

Market Cap Rank

#9440 Global

#55 in Netherlands

Share Price

€1.13

Change (1 day)

-0.04%

52-Week Range

€0.84 - €1.78

All Time High

€1.78